Accueil>>Signaling Pathways>> Angiogenesis>> Integrin>>Zaurategrast ethyl ester sulfate

Zaurategrast ethyl ester sulfate

Catalog No.GC37962

Le sulfate d'ester éthylique de Zaurategrast (sulfate de CDP323), le promédicament ester éthylique de CT7758, est un antagoniste de l'intégrine α4β1/α4β7 utilisé pour le traitement des maladies inflammatoires et auto-immunes.

Products are for research use only. Not for human use. We do not sell to patients.

Zaurategrast ethyl ester sulfate Chemical Structure

Cas No.: 1214261-78-5

Taille Prix Stock Qté
5mg
190,00 $US
En stock
10mg
334,00 $US
En stock
25mg
656,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758[1], is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders[2]. α4β1/α4β7 integrin[1]

Zaurategrast ethyl ester sulfate (CDP323 sulfate), an ethyl ester prodrug of CT7758, shows some improvements in increasing mass transfer[1].

[1]. Chanteux H, et al. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. Drug Metab Dispos. 2015 Sep;43(9):1381-91. [2]. Davenport RJ, et al. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases• Drug Discov Today. 2007 Jul;12(13-14):569-76.

Avis

Review for Zaurategrast ethyl ester sulfate

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Zaurategrast ethyl ester sulfate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.